Curevac Logo

Curevac

A biopharmaceutical company developing therapies based on messenger RNA (mRNA) technology.

CVAC | F

Overview

Corporate Details

ISIN(s):
NL0015436031
LEI:
724500BUT8GAG9LMYN56
Country:
Germany
Address:
Friedrich-Miescher-Strasse 15, 72076 Tübingen

Description

CureVac is a global biopharmaceutical company specializing in the development of therapies based on messenger RNA (mRNA) technology. With over two decades of experience, the company engineers mRNA as a data carrier to instruct the human body to produce its own therapeutic proteins to combat a wide range of diseases. Its development pipeline focuses on creating transformative medicines, including prophylactic vaccines for infectious diseases and other therapeutic applications. CureVac collaborates with partners like GSK to advance its high-value mRNA programs, such as its seasonal influenza vaccine candidate.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-26 00:46
CureVac Announces Voting Results of Extraordinary General Meeting
English 20.3 KB
2025-11-24 13:10
CureVac Announces Financial Results for the Third Quarter and First Nine Months…
English 72.8 KB
2025-08-15 13:27
CureVac Announces Financial Results for the Second Quarter and First Half of 20…
English 25.8 KB
2025-08-08 02:15
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech
English 11.5 KB
2025-06-24 22:09
CureVac Announces Voting Results of General Meeting
English 10.0 KB
2025-05-20 13:00
CureVac Announces Financial Results for the First Quarter of 2025 and Provides …
English 23.3 KB
2025-05-15 22:10
CureVac Receives Additional Positive Validity Decision from European Patent Off…
English 12.1 KB
2025-04-10 13:12
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 a…
English 39.8 KB
2025-04-09 13:00
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Busin…
English 10.4 KB
2025-04-07 13:00
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for …
English 14.7 KB
2025-03-27 21:05
CureVac Receives Positive Validity Decision from European Patent Office in Liti…
English 11.9 KB
2025-02-19 13:03
CureVac Earns Repeat Recognition by LexisNexis as One of the Worlds Top Innovat…
English 12.2 KB
2025-02-18 13:03
CureVac Earns Repeat Recognition by LexisNexis as One of the Worlds Top Innovat…
English 12.2 KB
2024-04-25 00:00 English 4.3 MB

Automate Your Workflow. Get a real-time feed of all Curevac filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Curevac

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Curevac via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advicenne Logo
A specialty pharmaceutical company developing treatments for rare renal diseases.
France
ALDVI
AegirBio AB Logo
A diagnostics company specializing in therapeutic drug monitoring for biological drugs.
Sweden
AEGIR
Aelis Farma Logo
Biopharmaceutical company developing CB1 receptor inhibitors for CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Clinical-stage company developing therapeutic applications for botulinum toxins.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics with integrated R&D and manufacturing.
Japan
2927
AGENUS INC Logo
A clinical-stage biotechnology company specializing in immuno-oncology therapies.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Biopharmaceutical company developing therapies for rare and genetically defined diseases.
United States of America
AGIO
AHN-GOOK PHARMACEUTICAL Co., Ltd. Logo
Develops and markets medicines, focusing on respiratory and cardiovascular treatments.
South Korea
001540
Akari Therapeutics Plc Logo
Develops next-gen antibody-drug conjugates using proprietary cancer-killing toxins.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
A biopharmaceutical company that develops and commercializes therapeutics for kidney disease.
United States of America
AKBA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.